Higher body mass index (BMI) after diagnosis is linked to better survival outcomes in patients with localized renal cell ...

In a retrospective analysis, patients with colon cancer taking GLP-1 agonists had a 62% lower risk of 5-year mortality ...

CagriSema was associated with significant reductions in blood pressure relative to the medications alone among patients with ...

Semaglutide therapy was associated with higher likelihood of passing low-risk cardiovascular thresholds among patients with ...

An investigational once-weekly amylin receptor agonist conferred substantial weight loss across six different dosing regimens for adults with overweight or obesity, researchers reported in a phase 2 ...

The prevalence of body mass index (BMI)-defined obesity (BDO) among US youth aged 8 to 19 years closely mirrored that of BDO with excess adiposity across age, sex, and race and ethnicity, according to ...

In general, people are considered to be at a healthy weight if their BMI is between 18.5 and 24.9. A BMI of 25 or more is considered overweight, while a BMI of 30 or higher is considered obesity.

A new study on the worldwide prevalence of ‘abdominal obesity’ tied belly fat in ‘normal’ weight people to hypertension, diabetes, and high cholesterol.

New research presented at the European Association for the Study of Diabetes Annual Meeting 2025 suggests that people who are underweight or at the lower end of a “healthy” body mass index (BMI) face ...

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...